Bay Area Breast Cancer SPORE investigators pursue translational research on development of novel, molecularly targeted therapeutic agents and on identification of molecular markers that predict disease recurrence or response to therapy. All projects are based on and contribute to our knowledge of the basic genetic and biological events that enable cancer genesis and progression. The suite of therapeutic and marker studies now under study address all aspects of breast cancer progression. This research is carried out in five Projects and four Cores. New ideas and investigators are bought into the SPORE through Developmental Project and Career Development awards. Project 1 is developing immunoliposomes for targeted delivery of a suite of therapeutic agents. Project 2 focuses on identification of markers that improve prediction of response to RTK pathway inhibitors. Project 3 is exploiting a new in vitro model of early cancer development to identify markers of risk and targets for chemoprevention. Project 4 is developing therapeutic agents that inhibit proliferation and induce apoptosis by forcing telomerase misfunction. Project 5 is a population-based effort to identify predictors of recurrence in women with DCIS. Core 1 provides administration and organizational support for all SPORE investigators. Core 2 collects and manages tissue resources and outcomes information on breast cancer patients for SPORE investigators. Core 3 supports preclinical evaluations of novel therapeutic agents in xenograft models. Core 4 supports the involvement of breast cancer advocates in SPORE research. Two current Development Projects are (a) exploring the utility of ductal lavage and nipple aspiration in identification of women at increased risk of developing breast cancer and (b) developing therapeutic antibodies to treat ERBB2 negative tumors. Two current Career Development awardees are (a) exploring the role of matrix metalloproteinase polymorphisms in cancer susceptibility and (b) developing an approach to breast cancer treatment using inhibitors of integrin signaling. The SPORE is located organizationally in the Cancer Center Breast Oncology Program and takes full advantage of 13 Cancer Center Cores.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058207-12
Application #
7035845
Study Section
Special Emphasis Panel (ZCA1-GRB-V (O1))
Program Officer
Kuzmin, Igor A
Project Start
1992-09-30
Project End
2007-11-30
Budget Start
2006-04-17
Budget End
2006-11-30
Support Year
12
Fiscal Year
2006
Total Cost
$2,426,332
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Rice, Megan S; Tamimi, Rulla M; Bertrand, Kimberly A et al. (2018) Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics. Breast Cancer Res Treat 170:129-141
Zhou, Yu; Zou, Hao; Yau, Christina et al. (2018) Discovery of internalizing antibodies to basal breast cancer cells. Protein Eng Des Sel 31:17-28
Campbell, Jeffrey I; Yau, Christina; Krass, Polina et al. (2017) Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 165:181-191
Campbell, Michael J; Baehner, Frederick; O'Meara, Tess et al. (2017) Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat 161:17-28
Bolan, Patrick J; Kim, Eunhee; Herman, Benjamin A et al. (2017) MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial. J Magn Reson Imaging 46:290-302
Olow, Aleksandra; Chen, Zhongzhong; Niedner, R Hannes et al. (2016) An Atlas of the Human Kinome Reveals the Mutational Landscape Underlying Dysregulated Phosphorylation Cascades in Cancer. Cancer Res 76:1733-45
Takai, Ken; Le, Annie; Weaver, Valerie M et al. (2016) Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget 7:82889-82901
Hu, Zhi; Mao, Jian-Hua; Curtis, Christina et al. (2016) Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer. Breast Cancer Res 18:70
Malkov, Serghei; Shepherd, John A; Scott, Christopher G et al. (2016) Mammographic texture and risk of breast cancer by tumor type and estrogen receptor status. Breast Cancer Res 18:122
Gu, Shenda; Hu, Zhi; Ngamcherdtrakul, Worapol et al. (2016) Therapeutic siRNA for drug-resistant HER2-positive breast cancer. Oncotarget 7:14727-41

Showing the most recent 10 out of 339 publications